Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of INC280 Plus Erlotinib in Patients With C-Met Expressing Non-Small Cell Lung Cancer

NCT01911507 is registered in ClinicalTrials.gov with University of California, Davis as lead sponsor.

NCT NCT01911507
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01911507 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of INC280 Plus Erlotinib in Patients With C-Met Expressing Non-Small Cell Lung Cancer
Lead sponsor
University of California, Davis
Phase
Phase 1
Overall status
Completed
Start date
August 27, 2013
Completion date
August 26, 2020
Enrollment
35 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent non-small cell lung cancer